Cargando…
Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana
BACKGROUND: Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for prevention of HIV infection in several clinical trials. Two studies of TDF PrEP among men who have sex with men showed slight bone mineral density (BMD) loss. We investigated the effect o...
Autores principales: | Kasonde, Michael, Niska, Richard W., Rose, Charles, Henderson, Faith L., Segolodi, Tebogo M., Turner, Kyle, Smith, Dawn K., Thigpen, Michael C., Paxton, Lynn A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953113/ https://www.ncbi.nlm.nih.gov/pubmed/24625530 http://dx.doi.org/10.1371/journal.pone.0090111 |
Ejemplares similares
-
Normal Laboratory Reference Intervals among Healthy Adults Screened for a HIV Pre-Exposure Prophylaxis Clinical Trial in Botswana
por: Segolodi, Tebogo M., et al.
Publicado: (2014) -
Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007) -
Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir
por: García-Lerma, J. Gerardo, et al.
Publicado: (2008) -
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018) -
Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis
por: Van Slyke, Loraine, et al.
Publicado: (2018)